TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01307891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane alone
Description: 100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane + Tigatuzumab
Description: Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
Study: NCT03717779

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: we perform a lung ultrasound to all the patients admitted for dyspnea independantly from the final diagnosis
Study: NCT00064103

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad5CMV-p53 gene
Description: Given intramucosally or as oral rinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01757860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARD-024
Description: Comparison of different dosages of drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Drug Carrier
Description: Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
Study: NCT02022046

Intervention type: OTHER
Intervention: Methylation biosignature
Description: Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
Study: NCT00160056

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hypoglycemia
Study: NCT00547248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Reconstituted with Tritanrix-Hep B before injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Reconstituted with Tritanrix-Hep B before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Reconstituted with Tritanrix-Hep B before injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix
Description: Reconstituted with Tritanrix-Hep B before injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Polio Sabin
Description: Oral, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin
Description: Oral, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Poliorix
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poliorix
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar (Wyeth)
Description: Intramuscular injection, 1 dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar (Wyeth)
Description: Intramuscular injection, 1 dose
Study: NCT01147718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: digoxin plus albiglutide
Description: A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
Study: NCT05468983

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical ( implants placement)
Description: 4 implants were placed interforamen of the mandibular arch by using the surgical guide

Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical ( implants placement)
Description: 4 implants were placed interforamen of the mandibular arch by using the surgical guide
Study: NCT02090283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101 dermal cream (6%)
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Study: NCT02033707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hallucinogens and psychoactive substances
Description: One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hallucinogens and psychoactive substances
Description: One of the following or placebo will be given:~Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis~Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem~Antihistamines: diphenhydramine, chlorpheniramine~Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion~Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine~Other: alcohol, scopolamine, nicotine~Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects.
Study: NCT03508349

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IST
Description: Women in the control group will receive routine care, which does not include testing for malaria with a rapid diagnostic test unless symptomatic for malaria. Women in the intervention group will receive this additional testing for malaria at each antenatal care, regardless of whether she is symptomatic for malaria.
Study: NCT03897569

Intervention type: OTHER
Intervention: frontal projection angle, ankle dorsiflexion
Description: Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat

Intervention type: OTHER
Intervention: frontal projection angle, ankle dorsiflexion
Description: Dorsiflexion measurements will be taken in 4 different positions and repeated and recorded 3 times in each position, Prone bent, straight knee and Standing bent, straight knee. Prior to the measurement, the participants completed two 30-second calf stretches The FPPA was determined as the angle at the knee formed by lines connecting the anterior superior iliac spine, the midpoint of the femoral condyles and the midpoint of the malleoli at the deepest part of the squat
Study: NCT03954002

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TTE and TOE
Description: A small flexible tube (TOE probe) will be inserted into your oesophagus, or food pipe, to take images of your heart as per routine anaesthetic care for cardiac surgery.~Just before and after general anaesthesia is administered, a short transthoracic echocardiography (TTE scan will be performed to acquire images of your heart. This is an ultrasound scan of your heart using a probe on the outside of the chest. During this period, relevant haemodynamic data such as blood pressure and heart rate will be recorded.
Study: NCT03837457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobomarsen
Description: At least weekly intravenous infusions of cobomarsen (282 mg) throughout study treatment period
Study: NCT01851655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plyometric Exercise
Description: Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric Exercise
Description: Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
Study: NCT01649115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles Passport
Description: The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
Study: NCT03654703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophophamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophophamide
Study: NCT04474808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: L-Arginin containing foot cream
Description: The participants apply one foot (randomized assignment) with the study cream twice a day (morning and evening) over a period of six weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urea-containing foot cream
Description: The participants apply one foot (randomized assignment) with the control cream twice a day (morning and evening) over a period of six weeks.
Study: NCT03320265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC-mAb
Description: Monthly treatment for 3 months (4 administrations)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Monthly treatment for 3 months (4 administrations)
Study: NCT04468893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Intervention Mental Health COVID-19
Description: The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Intervention Mental Health COVID-19
Description: The Online Intervention Mental Health COVID-19 aims to provide to the target population a self-applied intervention based primarily on Positive Psychology, aimed at the recognition and development of strengths and virtues from the well-being approach. In addition, it is supported by elements of Cognitive Behavioral Therapy such as the components of emotion and the Antecedent-Response-Consequence (ARC) model of emotions. Elements of Behavioral Activation Therapy are also included, such as the importance of physical exercise and the relationship between physical anxiety and its effects on anxiety and depression. The intervention is made up of 15 modules that are adapted to the symptoms that the population may suffer from the global contingency caused by the COVID-19 pandemic. In addition to the Positive Psychology modules, a module with psychoeducation on grief and loss was added.
Study: NCT03609814

Intervention type: DRUG
Intervention: Clofarabine
Description: Given IV

Intervention type: DRUG
Intervention: Fludarabine Injection
Description: Given IV
Study: NCT02453880

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Behavioral Therapy
Description: Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session.
Study: NCT00603603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 80% inhaled oxygen via non-rebreather mask
Description: Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30% inhaled oxygen via nasal cannula
Description: Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
Study: NCT00452660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exjade
Study: NCT04715282

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epley maneuver
Description: Epley maneuver

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epley maneuver
Description: Epley maneuver
Study: NCT01491867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: travoprost 0.003%
Description: Instillation of travoprost 0.003% 1/die in both eyes for 3 months
Study: NCT01947101

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
Study: NCT00882271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Ten Acupuncture treatments within six weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Ten Acupuncture treatments within six weeks
Study: NCT02030262

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiretinal membrane peeling with fluid-air exchange
Description: The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epiretinal membrane peeling with fluid-SF6 exchange
Description: The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
Study: NCT02239445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chloral hydrate Group
Description: chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose dexmedetomidine group
Description: Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose dexmedetomidine group
Description: Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
Study: NCT02791529

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocautery
Description: Skin incision performed by electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel
Description: Skin incision performed by scalpel
Study: NCT01544790

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
Study: NCT04438356

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: M-Health
Description: The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: M-Health
Description: The study was randomized (wait-list-control), and it was estimated that 80 subjects were randomly assigned to the immediate treatment group and the wait-list-control group. The two groups were tested for baseline before intervention in the mHealth. After the first questionnaire evaluation, the experimental group was involved in the mHealth for three months, and after three months, the experimental group and the waiting intervention control group were post-tested. To assess the effectiveness of the two groups before and after the mHealth . Control group that waits for intervention in the fourth month from the beginning of the fourth month to the end of the sixth month.
Study: NCT03049683

Intervention type: OTHER
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Description: The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).

Intervention type: OTHER
Intervention: Vestibular evoked myogenic potentials (VEMPs)
Description: The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
Study: NCT00915057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL972
Description: Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
Study: NCT01456182

Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 1

Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 2

Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 3

Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 4

Intervention type: DRUG
Group type: OTHER
Intervention: AFX-2
Description: Dose level 5
Study: NCT02586103

Intervention type: DEVICE
Intervention: MRI simulation
Description: It is not a working MRI machine but sounds and feels just like the real machine.
Study: NCT02010047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALK qPCR assay
Description: 72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
Study: NCT01766921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted H5N1 pandemic influenza vaccine
Description: Comparison of two doses of aH5N1c vaccine
Study: NCT04029675

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C is a strong antioxidant and has been shown to regenerate other antioxidants such as vitamin E, vitamin C also play an important role in immune function
Study: NCT03623048

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: antibacterial and anti-inflammatory mouthwash

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: anti-inflammatory cleansing mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propolis extract
Description: antibacterial mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pomegranate extract
Description: antibacterial mouthwash